Casandra
Casandra Test Code QD19559Version 1 (DRAFT)
Performing Lab
RET Sequencing and Deletion/Duplication
Clinical Use
Order TestUse
This test is used to identify individuals with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome by detecting single‑nucleotide variants, deletions, and duplications in the RET gene, which encodes the proto‑oncogene tyrosine‑protein kinase receptor Ret protein. Clinical indications include individuals with a clinical diagnosis of MEN2 (including MEN2A or MEN2B), medullary thyroid cancer (MTC), and primary C‑cell hyperplasia; informed consent and genetic counseling are strongly recommended.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
NGS (Targeted)
Biomarkers
RET
GeneSNV/Indel • Mutation • Categorical (e.g., Positive / Negative / Indeterminate)
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Not provided.
Related Tests
Other tests from different labs that may be relevant
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing
ARUP Laboratories
Multiple Endocrine Neoplasia Type 2A (MEN2A), Type 2B (MEN2B), and Familial Medullary Thyroid Carcinoma (FMTC) via the RET Gene
Prevention Genetics
VistaSeq® RET Comprehensive Analysis
Labcorp
Multiple Endocrine Neoplasia Type 2 Syndrome, RET, Full Gene Analysis, Varies
Mayo Clinic Lab
Multiple Endocrine Neoplasia Type 1 (MEN1) Sequencing and Deletion/Duplication
ARUP Laboratories
Hereditary Thyroid Cancer Panel, Sequencing and Deletion/Duplication
ARUP Laboratories
Hereditary Paraganglioma-Pheochromocytoma Expanded Panel, Sequencing and Deletion/Duplication
ARUP Laboratories
VistaSeq® MEN1 Comprehensive Analysis
Labcorp
VistaSeq® Endocrine Cancer Panel
Labcorp
Multiple Endocrine Neoplasia Type 1 (MEN1)
Ambry Genetics